- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04290689
Can Gait Analysis and Ultrasound Detect a Change in Calf Musculature in Children With Cerebral Palsy?
Can Gait Analysis and Imaging Methods Detect Change in the Calf Musculature in Children With Cerebral Palsy? Comparison Study of Toe Walking Patients Following Serial Casting, Botulinum Toxin-A and Typically Developing Controls.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to investigate the impact on gait and morphology of the calf muscle in children with Cerebral Palsy with equinus gait pattern following serial casting and Botulinum toxin (Btx) interventions.
Toe walking is a common feature of a number of orthopaedic and neurological problems (e.g. cerebral palsy, idiopathic toe walking and stroke). Patients who toe walk often develop contractures in their calf muscles and in the longer term may suffer from foot or calf pain and foot deformities. Toe walking also causes difficulties with balance and leads to secondary compensations and deformities. The causes of toe walking are not always clear for individual patients. Current interventions target the perceived causes (e.g. surgery, stretching or orthotics for contracture or botulinum toxin injections for excessive activity) but the relationship between toe walking and the impairment in muscle morphology and control is not fully understood. Clinical movement analysis is used to quantify joint motion and loading during gait. This is done according to established local departmental protocol and is part of routine clinical practice. This is done using the Video Based Motion Analysis System Ltd (VICON), which is a 3D movement analysis modality which makes use of small, spherical reflective markers, between 5mm and 25mm in diameter that are attached to the skin over key anatomical landmarks (located during the clinical examination). Special infrared cameras are used to track the movements of reflective markers in three dimensions. This is combined with AMTI force plates; which together give the kinematics and kinetics of the subject. Electromyography (EMG) of the Triceps Surae and Tibialis Anterior enables observation of muscle activity in conjunction with the gait cycle during different movements. After obtaining participant consent and ensuring that the participant fully understands the scope of the tasks, the session is undertaken. In brief, using local ORLAU department protocol, a clinician places reflective markers on the subject and anthropometric measurements are taken. After the subject is prepared, they are asked to walk along a 10-metre walkway at a self selected speed and a minimum of 6 trials are collected with adequate strikes with each foot landing on the force plate to obtain desired kinematic and kinetic data. EMG recordings are performed simultaneously on the Medial & Lateral Gastrocnemius, Soleus, and Tibialis Anterior to record muscle activity during the movement.
To obtain information about the morphology, the modality of B-mode ultrasound evaluated the muscle morphology and obtains key information such as muscle fibre length, fibre orientation, pennation angle, cross sectional area, and muscle thickness. After obtaining consent and ensuring that the participant understands fully the scope of the session, they are asked to lie prone on the plinth with lower legs exposed so that the assessor has access to the calf muscles. The assessor then uses the b-mode ultrasound protocol to obtain the key parameters of the calf muscle. Muscle lengths are measured using a Vernier caliper.
In addition, the imaging modality elastography is used. This uses mechanical force, from manual pressure or through a shear wave impulse generated within the ultrasound probe, to detect the change in deformation of the examined tissue and therefore to determine the stiffness. The stiffness of soft tissues can be an indication of pathology. Elastography uses harmless ultrasound waves and allows for the visualisation of strain across a tissue, by superimposing the colour coded elasticity map onto a conventional B-mode image. The colours represent the stiffness of the tissue ranging from red to green to blue, with the exact scale varying between vendors. Shear wave elastography has the added advantage of being able to provide velocity measurements within a defined region of interest, thus quantifying tissue stiffness.
Prior to beginning the session, consent from the subject is obtained and the scope of the session is explained. After consent from the participant, the subject is asked to lie prone on the plinth with their lower legs exposed. The consultant radiologist undertakes elastography measures on the calf muscles (medial, lateral gastrocnemius, soleus) in longitudinal and transverse planes according to the protocol. These are then saved after the key information is obtained and analysed after the session.
Computer modelling can estimate muscle forces during gait, and it is used to study a wide range of conditions such as spastic paresis and crouch gait. Ultrasound can provide information about muscle parameters such as volume, length, anatomical cross-sectional area and pennation angle. This information can be used to adjust the parameters of the musculoskeletal model to fit the characteristics of each patient. The musculoskeletal model can then estimate personalised muscle forces and help understand the individual impairments which lead to toe walking. Future prospects Clinical- The computer models will assist with the precise identification of impairments (eg muscle atrophy, contracture and spasticity) and hence allow more objective specification and targeting of interventions. Combining the data collected from B mode ultrasound, elastography and gait analysis, the effects of clinical interventions in muscle properties can be observed. This can be applied to other interventions, including orthopaedic surgery and orthotic devices. Elastography can also be a vital tool in understanding the elastic muscle properties associated with myopathies and can help optimise and personalise care by selecting the most effective intervention based on an individual's baseline features.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Shropshire
-
Oswestry, Shropshire, United Kingdom, SY10 7AG
- Recruiting
- ORLAU, RJAH Orthopaedic Hospital
-
Contact:
- Claire Wright
- Phone Number: 0044 1691 404139
- Email: clairewright8@nhs.net
-
Contact:
- Caroline Stewart, PhD
- Phone Number: 0044 1691 404666
- Email: caroline.stewart9@nhs.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants must be diagnosed with Cerebral Palsy and have a planned intervention of serial casting or botulinum toxin calf injection or serial casting and botulinum toxin injection.
- Participants must be able to walk 10 metres barefoot.
- Participants must be between the ages of 4 and 16.
- Participants must have a gait pattern showing persistent toe walking or premature heel rise.
- Participants should be able to comply with requests to walk in the gait laboratory.
Exclusion Criteria:
- Participants who have had Botulinum toxin-A calf injections or previous serial casting within the last 6 months.
- Participants should not have fixed foot equinus.
- Participants must not have any learning difficulties which would prevent compliance with the standard protocols.
- Participants must not have had any previous surgical interventions of the lower limbs within one year of taking of taking part.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Botulinum Toxin-A injection treatment
Toe walking Cerebral Palsy subject who are subject to Botulinum toxin-A injection treatment.
The dosage will be determined by the Orthopaedic Consultant
|
Botulinum Toxin-A injection to be administered by the surgeon to the subject's calf muscle as per normal clinical protocol to help improve muscle tone.
Other Names:
|
Serial casting stretching treatment
Toe walking Cerebral Palsy subject who are subject to serial casting stretching treatment.
|
Stretching cast intervention to be carried out in clinic as per normal clinical protocol.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Are there gait (kinetic) differences pre and post intervention in toe walking cerebral palsy subjects?
Time Frame: up to12 weeks
|
Kinetics (joint forces) will be measured (using gait analysis modality) pre and post intervention in toe walking cerebral palsy subjects.
The intervention will be determined by the consultant Orthopedic Surgeon in clinic.Units of measure:measured in Nm/kg
|
up to12 weeks
|
Are there gait (kinematic) differences pre and post intervention in toe walking cerebral palsy subjects?
Time Frame: up to 12 weeks
|
Kinematics (joint angles) will be measured (using gait analysis modality) pre and post intervention in toe walking cerebral palsy subjects.
The intervention will be determined by the consultant Orthopedic Surgeon in clinic.Units of measure: measured in degrees (angle).
|
up to 12 weeks
|
Triceps Surae muscle activation during the gait cycle (Electromyography)
Time Frame: up to12 weeks
|
Electromyography (EMG) measurement - is the muscle activated or deactivated pre and post intervention in toe walking cerebral palsy subjects?
Measured in uV
|
up to12 weeks
|
Are there morphological differences in the calf muscle pre and post serial casting/botulinum toxin-A intervention in toe walking cerebral palsy subjects?
Time Frame: up to 12 weeks
|
B-mode ultrasound modality will be used pre and post intervention to measure muscle morphology parameter - muscle thickness.
Measured in millimeter
|
up to 12 weeks
|
Are there morphological differences in the calf muscle pre and post serial casting/botulinum toxin-A intervention in toe walking cerebral palsy subjects?
Time Frame: up to 12 weeks
|
B-mode ultrasound modality will be used pre and post intervention to measure muscle morphology parameter - muscle fibre length; measured in millimeter
|
up to 12 weeks
|
Are there morphological differences in the calf muscle pre and post serial casting/botulinum toxin-A intervention in toe walking cerebral palsy subjects?
Time Frame: up to 12 weeks
|
B-mode ultrasound modality will be used pre and post intervention to measure muscle morphology parameter - muscle length; measured in millimeter
|
up to 12 weeks
|
Are there morphological differences in the calf muscle pre and post serial casting/botulinum toxin-A intervention in toe walking cerebral palsy subjects?
Time Frame: up to 12 weeks
|
B-mode ultrasound modality will be used pre and post intervention to measure muscle morphology parameter - pennation angle; measured in degrees.
|
up to 12 weeks
|
Are there morphological differences in the calf muscle pre and post serial casting/botulinum toxin-A intervention in toe walking cerebral palsy subjects?
Time Frame: up to 12 weeks
|
B-mode ultrasound modality will be used pre and post intervention to measure muscle morphology parameter - Cross sectional area; measured in cm^2
|
up to 12 weeks
|
Difference in the muscle stiffness values (using elastography) in the calf muscle pre and post intervention.
Time Frame: up to 12 weeks
|
To determine, using elastography modality, if there is a difference in muscle stiffness values pre and post intervention for toe walking cerebral palsy children.
Units of measure: m/s velocity
|
up to 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Are there gait (kinetic and kinematic) differences pre and post intervention in toe walking cerebral palsy subjects?
Time Frame: up to 12 weeks
|
The temporospatial parameter during the gait analysis will be measured pre and post intervention: walking speed; units of measure:m/s
|
up to 12 weeks
|
Are there gait (kinetic and kinematic) differences pre and post intervention in toe walking cerebral palsy subjects?
Time Frame: up to 12 weeks
|
The temporospatial parameter during the gait analysis will be measured pre and post intervention: cadence; units of measure: steps/min
|
up to 12 weeks
|
Are there gait (kinetic and kinematic) differences pre and post intervention in toe walking cerebral palsy subjects?
Time Frame: up to 12 weeks
|
The temporospatial parameter during the gait analysis will be measured pre and post intervention: single/double support ; units of measure: single/double
|
up to 12 weeks
|
Are there gait (kinetic and kinematic) differences pre and post intervention in toe walking cerebral palsy subjects?
Time Frame: up to 12 weeks
|
The temporospatial parameter during the gait analysis will be measured pre and post intervention:step width; units of measure: meter
|
up to 12 weeks
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Armand S, Decoulon G, Bonnefoy-Mazure A. Gait analysis in children with cerebral palsy. EFORT Open Rev. 2016 Dec 22;1(12):448-460. doi: 10.1302/2058-5241.1.000052. eCollection 2016 Dec.
- Barber L, Barrett R, Lichtwark G. Passive muscle mechanical properties of the medial gastrocnemius in young adults with spastic cerebral palsy. J Biomech. 2011 Sep 2;44(13):2496-500. doi: 10.1016/j.jbiomech.2011.06.008. Epub 2011 Jul 16.
- Blemker SS, Asakawa DS, Gold GE, Delp SL. Image-based musculoskeletal modeling: applications, advances, and future opportunities. J Magn Reson Imaging. 2007 Feb;25(2):441-51. doi: 10.1002/jmri.20805.
- Stewart C, Shortland AP. The biomechanics of pathological gait - from muscle to movement. Acta Bioeng Biomech. 2010;12(3):3-12.
- Kalsi G, Fry NR, Shortland AP. Gastrocnemius muscle-tendon interaction during walking in typically-developing adults and children, and in children with spastic cerebral palsy. J Biomech. 2016 Oct 3;49(14):3194-3199. doi: 10.1016/j.jbiomech.2016.07.038. Epub 2016 Aug 8.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Brain Damage, Chronic
- Cerebral Palsy
- Paralysis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- RL1 777
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebral Palsy
-
Gazi UniversityCompletedCerebral Palsy | Cerebral Palsy, Spastic | Cerebral Palsy Spastic Diplegia | Cerebral Palsy Quadriplegic | Cerebral Palsy, MonoplegicTurkey
-
Northwestern UniversityActive, not recruitingCerebral Palsy | Diplegic Cerebral Palsy | Bilateral Cerebral PalsyUnited States
-
Centre Médico-Chirurgical de Réadaptation des Massues...RecruitingCerebral Palsy, Dyskinetic | Cerebral Palsy, Spastic | Infantile Hemiplegic Cerebral PalsyFrance
-
St Mary's University CollegeUniversity of GloucestershireUnknownCerebral Palsy | Cerebral Palsy Ataxic | Cerebral Palsy, MixedUnited Kingdom
-
Hilde FeysHasselt University; ETH Zurich; Curtin UniversityRecruitingHemiplegic Cerebral Palsy | Cerebral Palsy, SpasticBelgium
-
University of California, San FranciscoNational Institutes of Health (NIH)RecruitingDystonic Cerebral Palsy | Dyskinetic Cerebral PalsyUnited States
-
East Carolina UniversityRecruitingHemiplegic Cerebral Palsy | Unilateral Cerebral Palsy | Remote Ischemic ConditioningUnited States
-
MTI UniversityEnrolling by invitationSpastic Diplegic Cerebral PalsyEgypt
-
October 6 UniversityCompletedSpastic Cerebral Palsy | Spastic Hemiplegic Cerebral PalsyEgypt
-
Marmara UniversityUnknownCerebral Palsy, Spastic | Cerebral Palsy, Spastic, DiplegicTurkey
Clinical Trials on Botulinum Toxin-A injection
-
YangHuiUnknown
-
HugelCompletedBenign Masseteric HypertrophyKorea, Republic of
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
Walter Reed Army Medical CenterUnknown
-
Seton Healthcare FamilyCompleted
-
HugelCompletedOveractive BladderKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.Completed
-
HugelCompletedCervical DystoniaKorea, Republic of
-
Khon Kaen UniversityUnknown
-
HugelRecruitingGlabellar LinesKorea, Republic of